Why attend

Cancer rates continue to rise globally with a disproportionate impact on the older population. Individuals aged 70 and above are particularly affected and account for the largest proportion of cancer-related deaths globally. Despite this, the care they receive falls short when compared to other age groups. The misconception that older adults have a lower treatment tolerance contributes to this, leading to under-representation in trial registration.  There is a strong emphasis from regulatory bodies on the need to include patients aged 75 and above. Yet, very often at the time of registration of new drugs, fewer older cancer patients are enrolled — resulting in skewed output of tolerance in the ‘non-fit’ older population.

Objective

The SIOG Masterclass offers world-class training to healthcare professionals who are treating older cancer patients, to address hidden inclusion criteria that inevitably exclude older cancer patients in randomised control trials.The course will help delegates develop protocol concept for clinical trials, ready for submission at their institutions.

Benefits

• A 4 day-course formatted to offer an exceptional educational experience
• Exclusive guidance by an international faculty  in geriatric oncology
• Unique opportunity to build your network in geriatric oncology research
• Access to SIOG Membership and its related benefits

Scientific Committee